인쇄하기
취소

Hanmi wins gemicitabine patent

Published: 2007-04-23 06:56:00
Updated: 2007-04-23 06:56:00
Hanmi Pharm announced on April it acquired a Korean patent related to a core technology of producing gemcitabine intermediate, entitled 1--halo-2,2-difluoro-2-deoxy-D-ribofuranose derivative and its manufacturing method.

Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, and breast cancer. It is being investigated for use in esophageal cancer, and is us...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.